Despite numerous strategies, the cure of multiple myeloma remains a difficult challenge. Recent approaches have involved dose-intensive therapy followed by stem cell transplantation, most often with autologous stem cells (ASCT). Although ASCT is of benefit, it is not considered curative. Between 1988 and 1995, we utilized an aggressive three-drug conditioning regimen followed by ABMT using marrow purged with either 4-hydroperoxycyclophosphamide (4-HC) or mafosphamide (MAF). Twenty-nine of 42 patients who had first received VAD (14 patients) or VAD followed by cyclophosphamide ( 
cure some individuals with this disease, [2] [3] [4] and the documentation of a 'graft-versus-myeloma' effect appears to contribute to this curative ability. 5, 6 However, allogeneic transplantation is associated with considerable toxicity and is limited to a minority of myeloma patients. 2, 3 Although most recipients eventually relapse, patients treated with dose-intensive therapy and autologous stem cell transplantation (ASCT) as part of initial therapy have a better outcome than those treated with conventional chemotherapy in phase II trials, as well as in randomized and comparative studies. [7] [8] [9] [10] Due to the results of such studies and its widespread availability, ASCT has become a standard of care in this disease.
The majority of multiple myeloma patients receiving ASCT as part of initial therapy achieve at least a PR, while 25-75% achieve a CR, albeit using variable response criteria. [7] [8] [9] [10] [11] [12] [13] [14] [15] Median actuarial progression-free survival has ranged from 2.5 to 4.0 years, with approximately 25% projected to be alive without progression from CR or PR at 5 years post ASCT. Median overall survival rates are of the order of 4.5-6.5 years. [7] [8] [9] [10] [11] [12] [13] [14] More prolonged follow-up data after ASCT in multiple myeloma is rather limited. A recent study by the Arkansas group, primarily in patients with refractory relapse, described 10-year event-free and overall survival rates of 11 and 19%, respectively, in a subset of patients conditioned with melphalan and TBI. 16 In the current report, we describe the long-term outcome of a cohort of patients grafted between 1988 and 1995 using ABMT purged with either 4-hydroperoxycyclophosphamide (4-HC) or mafosphamide (MAF). Results in the first 14 patients have been previously reported.
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Patients and methods
Between August 1988 and December 1995, 42 multiple myeloma patients were entered on to one of two ABMT studies. In the first, patients were initially given VAD (vincristine, doxorubicin and dexamethasone), as previously described, for two to four cycles. 18 In the second study, patients received one cycle of VAD, followed by a regimen of high-dose cyclophosphamide (HD-CY) 7 g/m 2 i.v. plus dexamethasone 40 mg p.o. for 4 days plus GM-CSF 250 g/m 2 i.v. until blood count recovery. Patients achieving a у50% reduction in the paraprotein level as well as р10% plasma cells in the marrow were eligible to undergo marrow harvest and ABMT. Twenty-nine of the 42 patients (70%) underwent ABMT, including 14 of 24 (58%) patients entered on the first study and 15 of 18 (83%) in the second study (Table 1) .
In patients eligible for ABMT, the median percent of marrow plasma cells after VAD alone was 2.5% (range Ͻ1-10%), compared with Ͻ1% (range 0-4%) in those who also received HD-CY. After HD-CY, three patients had normal protein studies by repeat electrophoresis. Immunofixation studies were not routinely obtained at this time, but were negative in two patients.
Bone marrow was harvested under general anesthesia and then purged with either 4-HC (23 patients) or, when 4-HC was unavailable, MAF (six patients) as reported previously. 17 If the total nucleated cell count was Ͻ4.0 ϫ 10 8 /kg, the entire marrow was treated with 4-HC as described below. If Ͼ4.0 ϫ 10 8 /kg was obtained, the majority was treated with 4-HC while the remainder (ෂ1.0 ϫ 10 8 /kg) was cryopreserved and held in reserve to be reinfused in case of poor engraftment. For 4-HC purging, a buffy coat was prepared by centrifuging the marrow for 5 min at 3000 r.p.m. in a Sorvall RC-c centrifuge. The hematocrit was adjusted to 7% in all patients. Incubation with 4-HC was performed at a final concentration of 100 g/ml x 30 min with mixing every 5 min. After 15 min, the mixture was refrigerated to 4°C. The supernatant was expressed, pooled at the level of the cells and the bone marrow frozen in a controlled-rate freezer at Ϫ1°C/min to Ϫ50°C and at Ϫ10°C/min to Ϫ80°C, then transferred to the liquid phase of the liquid nitrogen freezer. The median number of mononuclear cells infused at ABMT was 2.26 ϫ 10 8 /kg (range 1.07-4.8).
Patients were conditioned with combinations of busulfan, cyclophosphamide and melphalan (BU ϩ CY ϩ MEL). The dose schedule for the first 14 patients has already been reported. 17 The remaining 15 patients were given a total Patients were hospitalized in private HEPA-filtered rooms. Dilantin prophylaxis was used to prevent busulfaninduced seizures; uro-prophylaxis consisted of hyperhydration. Irradiated blood products, antibiotics, and anti-fungal agents were given as needed. Post ABMT, alfa-interferon maintenance therapy was commenced when the ANC was у1.5 ϫ 10 9 /l and the platelet count was у75 ϫ 10 9 /l. Alfainterferon was begun at a dose of 1 MU s.c. thrice weekly and increased to 3 MU/m 2 three times a week as tolerated. Alfa-interferon was continued until relapse occurred or toxicity supervened.
Due to constraints of the health care system, ␤2-microglobulin levels were not available in all patients. Bone marrow cytogenetics were also not routinely obtained in these patients. The generation of an allele-specific oligonucleotide PCR probe, involving characterization of the CDR3 region of the rearranged immunoglobulin heavy chain gene, to use for subsequent monitoring of minimal residual disease, was attempted in cryopreserved marrow specimens from several patients. 19 Due either to an insufficient number of plasma cells in the specimen, or to technical difficulties, patient-specific probes were not feasible.
Patients were re-evaluated for anti-tumor response at day ϩ100 post ABMT, then every 3-6 months thereafter.
Definitions of response
CR was defined as the absence of the original paraprotein by electropheresis and immunofixation of the blood and/or urine, р5% plasma cells in the bone marrow and no evidence of an increase in the number or size of skeletal lesions on radiographs. PR required a Ͼ50% decrease in paraprotein level with no increase in bony lesions.
Relapse from CR was defined as the reappearance of the original paraprotein on electropheresis or immunofixation, an increase in the number of marrow plasma cells to Ͼ5%, hypercalcemia or the development of new plasmacytomas or skeletal lesions. Progression from PR included an increase in paraprotein level of Ͼ25%, increase in the number and size of skeletal lesions or plasmacytomas or the development of hypercalcemia. 15 
Statistical considerations
Progression-free survival was calculated from the day of ABMT until the time of progression or relapse. Patients were censored at the time of relapse or death from any cause. Overall survival was calculated from the time of ABMT until the occurrence of death from any cause. Patients were censored at the date of last follow-up. The method of Kaplan-Meier was used to calculate these parameters. 20 Results Table 1 shows the characteristics of the 29 patients who underwent bone marrow harvest and ABMT. Table 2 outlines their transplant-related characteristics. After ABMT, the median day to achieve an ANC у0.5 ϫ 10 9 /l was 19 (range [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] in those who had received VAD alone vs 25 (range 12-68) in patients also given HD-CY before harvest. The median number of days to the last platelet transfusion was 31 (range 10-46) and 53 (range 32-1285), respectively.
At day ϩ100 post ABMT, nine patients were in a CR (three after prior VAD alone and six after VAD ϩ HD-CY), while 14 had entered a PR. Six patients were not evaluable due to early fatal toxicity, including three who had received VAD alone and three who had been given VAD ϩ HD-CY. Five of these died of early regimenrelated toxicity due to hepatic VOD (days ϩ23, ϩ51, ϩ61, ϩ62) or CNS edema (day ϩ30), while a candidal infection was fatal on day ϩ46 in another.
Alpha-interferon was initiated in 12 patients. Three patients remain on the drug 5-7 years post ABMT, while the remainder have discontinued interferon due to the development of pemphigus (one patient), autoimmune hepatitis (one patient), relapse (four patients), poor tolerance (one patient), and physician discretion after 2-5 years of therapy (two patients).
Two patients succumbed to late non-relapse mortality. In one, progressive pulmonary toxicity was fatal 1.5 years post ABMT, while another developed autoimmune hepatitis while on alpha-interferon and died 1.4 years after the procedure. One additional patient is undergoing treatment of a sarcoma of the lower extremity 8 years post ASCT.
Fifteen of the 29 patients (52%) have relapsed at a median of 1.8 years (range 0.4-7.5) post ABMT. Three of these had achieved a CR and 12 a PR. Fourteen of them experienced both laboratory and clinical evidence of recurrent myeloma. One of these individuals who presented with stage IIIB disease at diagnosis is alive and continues to receive monthly dexamethasone and intermittent local radiotherapy as needed 11.25 years post BMT. Another complete responder patient has had progression manifest only by recurrence of the original paraprotein serum on immunofixation, 7.5 years post ABMT, and is alive at 8.5 years post ASCT.
Five individuals have remained in CR for a median of 7.5 years (range 5.8-8.0 years). Two patients remain in Table 3 outlines the characteristics of the seven patients who are alive without progressive disease. At a median follow-up of 7.5 years (range 5.0-11.25 years) after ASCT, the actuarial progression-free survival rate is 27% (95% CI 13-44%) (Figure 1 ) while the actuarial overall survival rate is 28% (95% CI 11-50%).
Discussion
Key elements of this study included careful selection of chemosensitive patients, conditioning with an aggressive three-drug regimen and use of marrow purged with one of two cyclophosphamide derivatives. As well, approximately one-half of patients received HD-CY before marrow harvest at a dose in the range of that used in pre-ASCT conditioning regimens; this measure resulted in a higher proportion of patients eligible for ABMT. Compared with current methodology, in which primed peripheral blood stem cells are utilized, hematologic recovery was prolonged after ABMT. In addition, the transplant-related mortality rate following the three-drug conditioning regimen was excessive by today's standards. Nevertheless, six patients remain in continuous CR or PR for periods exceeding 6 years for a long-term progression-free survival rate of 27%. Five of these individuals have an excellent quality of life.
Previous gene marking studies in patients with other malignancies have demonstrated that both reinfusion of malignant cells with the autograft, as well as residual tumor in the patient, can contribute to post-ASCT relapse. 21 In multiple myeloma, a recent comparison of patients receiving autologous or syngeneic stem cell transplants demonstrated a significantly higher relapse rate in autografted patients, 22 a finding that supports continued efforts to obtain a stem cell source free of tumor. However, the relative contributions of inadequate purging vs the failure to eradicate all the endogenous tumor cells are unclear from myeloma studies to date. The latter mechanism is clearly important, as disease recurrences are also common after allogeneic and syngeneic grafts. 22 On the other hand, morphologic, immunophenotypic or molecular evidence of myeloma has often been present in bone marrow, and more recently, blood stem cells harvested for transplantation, 12, 17, 23 and a higher percentage of plasma cells in the marrow correlated with a lower CR rate in one study. 12 Purging with 4-HC or MAF was used in the current study to eliminate such unwanted cells. 4-HC, in doses suitable for clinical use, has been reported to effect greater than a four-log tumor reduction in myeloma cell lines. 24 Additional studies in mice have demonstrated that incubation of a mixture of myeloma and normal bone marrow cells with 4-HC can eliminate the tumor cells. Purged marrow cells were able to reconstitute normal hematopoiesis in myeloblated animals, without the subsequent development of myeloma. In contrast, control mice given unmanipulated marrow mixtures experienced rapid occurrence of plasma cell tumors. 25 More recently, a number of groups have evaluated the selection of CD34-positive cells in the PBSCs to try to ␤2-M = ␤2-microglobulin; 1 rel = 1st relapse; Dx = diagnosis; ␣-IFN = alpha-interferon; VAD = vincristine, doxorubicin, dexamethasone; HD-CY = highdose cyclophosphamide ϩ dexamethasone ϩ GM-CSF; NS = nonsecretory; LC = light chain. reduce tumor contamination. CD34-positive cell selection reliably produces a several-log depletion of malignant cells as assessed by sensitive PCR-based studies, and the products of some patients can be rendered PCR negative. 26, 27 However, only a minority of patients autografted with PBSCs, even if positively selected, can achieve PCR negativity after ASCT, which has been considered a prerequisite for complete disease eradication. 28 Moreover, a recent randomized trial utilizing BU ϩ CY has shown that patients receiving selected blood stem cells had no advantage over those given unmanipulated grafts in terms of overall or progression-free survival. 27 Our study design did not allow assessment of the role of purging for long-term survivorship.
As in other studies of ASCT, late complications decreased our survival rate. 29 Two patients in this series died over 1 year post ASCT of non-relapse causes probably related to their therapy. Although no cases of secondary myelodysplastic syndrome or acute leukemia (MDS/AML) were observed, one secondary solid tumor occurred. Recent data suggest that secondary MDS/AML post ASCT is primarily related to the extent of prior cytotoxic therapy. 30, 31 The risk factors for post-ASCT solid tumors are less welldefined. As in our series, such tumors may have a long latency period post ASCT, and patients will need to be followed for prolonged periods to ascertain the true impact of such complications. 29 In addition, late recurrences have been observed after allogeneic, syngeneic and autologous transplantation for multiple myeloma. 3, 8, 13, 22 One patient in CR in this series experienced a relapse, detected by immunofixation alone, 7.5 years post ASCT. Unfortunately, only conventional laboratory techniques were available to monitor the disease status. It is certainly possible that laboratory or clinical evidence of recurrent myeloma may become evident in more of our patients as they are followed for even longer time periods.
Despite the shortcomings discussed above, the results of this study indicate that durable CR can occur after ASCT and raise the provocative question of whether this procedure can ever be curative in multiple myeloma. Although our regimen produced substantial toxicity, newer strategies to achieve high levels of cytoreduction with two separate dose-intensive regimens, each followed by PBSC transplantation, have yielded encouraging results. In particular, the non-relapse mortality rates have been low while the CR rate has been reported to increase after each transplant. 9, 32 Similarly, our second study involved the pre-harvest administration of CY at a sufficiently high dose that it could be considered the first of two dose-intensive regimens, with GM-CSF 'substituting' for ASCT. Of note, six of the seven long-term progressive-free survivors, and all of those remaining in continuous CR had received such 'double' dose-intensive therapy.
Recent efforts to increase dose intensity in multiple myeloma have involved escalation of the dose of melphalan beyond the maximum dose of 200 mg/m 2 usually used as single-agent conditioning. An Italian group has reported preliminary but encouraging results with 220 mg/m 2 of melphalan, 33 while we have used even higher doses along with amifostine to try to reduce mucosal toxicity. 34 Preliminary results from the University of Arkansas Health Sciences Center indicate the administration of additional cycles of conventional chemotherapy after ASCT may be beneficial. 35 Continued pursuit of such dose-intensive strategies, along with other measures to reduce the myeloma burden such as immunotherapy 36 or thalidomide 37 are clearly warranted. Prolonged follow-up will be required to accurately determine the benefit of ASCT-based therapy in patients given very aggressive dose-intensive regimens.
